At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 636 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Dulaglutide for Type 2 Diabetes. Completed, enrolled 636 participants across 46 sites.
Detailed Summary
The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective and safe compared to dulaglutide in participants with type 2 diabetes in Japan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 2019
Enrollment StartMay 2019
Primary CompletionMar 2021
Study CompletionMar 2021
TodayJul 2026
First PostedMar 4, 2019
Enrollment StartMay 7, 2019
Primary CompletionMar 10, 2021
Study CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.3 years ago
Interventions
Tirzepatidedrug
Administered SC
Dulaglutidedrug
Administered SC